P reeclampsia is a pregnancy disorder occurring in ≈2% to 8% of women and is associated with an increase in morbidity and mortality to both mothers and fetuses. [1] [2] [3] [4] Preeclampsia is identified by high blood pressure and abnormal uterine artery Doppler sonography in the presence or absence of proteinuria near the 20th week of gestation. Although the pathophysiologic mechanisms of preeclampsia remain unknown, the placenta is implicated in being the central culprit in this disease stimulating circulating factors responsible for hypertension and impairing maternal endothelium-dependent responses.
P reeclampsia is a pregnancy disorder occurring in ≈2% to 8% of women and is associated with an increase in morbidity and mortality to both mothers and fetuses. [1] [2] [3] [4] Preeclampsia is identified by high blood pressure and abnormal uterine artery Doppler sonography in the presence or absence of proteinuria near the 20th week of gestation. Although the pathophysiologic mechanisms of preeclampsia remain unknown, the placenta is implicated in being the central culprit in this disease stimulating circulating factors responsible for hypertension and impairing maternal endothelium-dependent responses. [4] [5] [6] [7] [8] Mediators of endothelial dysfunction, such as increased production of the vasoconstrictor ET-1 (endothelin-1), antiangiogenic factor sFlt-1 (soluble vascular endothelial growth factor receptor 1), and decreased of vasodilators, such as nitric oxide (NO), are thought to play a role in the development of hypertension and possibly reduced fetal weight in preeclamptic women. In addition, a significant increase in inflammatory cytokines, such as TNF-α (tumor necrosis factor-α) and IL-6 (interleukin-6), has been observed in preeclampsia and proposed to stimulate factors that play a role in vasoconstriction and hypertension during pregnancy. [9] [10] [11] [12] [13] [14] In fact, studies performed by our laboratory have shown that the normal pregnant (NP) recipient rats implanted with a mini osmotic pump infusing either TNF-α or IL-6 exhibit many characteristics of preeclampsia. 15, 16 Studies in our preeclamptic normal pregnant patients indicate that preeclampsia is associated with a progesterone deficiency. 17 Our in vitro studies have shown that progesterone suppresses ET-1 levels in response to human umbilical venous endothelial cells cultured with either serum from reduced uterine perfusion pressure (RUPP) or preeclamptic patients. 17 Furthermore, we have published that 17-hydroxyprogesterone caproate (17-OHPC), progesterone derivative, administered on day 18 of gestation (GD18) attenuates many clinical characteristics of preeclampsia in the RUPP rat model. In fact, administration of GD18 17-OHPC improves hypertension and vasoconstrictors in rat models of elevated cytokines, either TNF-α or IL-6, during pregnancy. [17] [18] [19] [20] Taken together, these findings suggest that 17-OHPC has both anti-inflammatory and antihypertensive effects, possibly by decreasing vasoconstrictor profiles stimulated by inflammatory mediators and thus improves maternal outcomes in our rat models of preeclampsia. However, our previous studies have not shown any effect of 17-OHPC in fetal weight. This may be because of the late term administration of 17-OHPC (GD18) to RUPP rats.
Importantly, many patients are diagnosed as early as 20-week gestation by abnormal Doppler sonography, having no treatment options available to improve uterine restriction or blood flow. Interestingly, this time frame also coincides with significant elevation in sFlt-1. Associated with these increases is the elevation in blood pressure, which has been coined the chicken and the egg debate. 21 We have recently shown that hypertension caused by infusion of sFlt-1 is associated with endothelial dysfunction characterized by increased ET-1 and decreased NO. 22 Although our previous study did not show profound changes in placental ET-1 with 17-OHPC, we do not know the effect it has on sFlt-1-reduced NO during pregnancy. Therefore, in the present study, we hypothesized that early administration of 17-OHPC on day 15 of gestation (GD15) after placental ischemia is induced could decrease sFlt-1 as a mechanism to improve NO and uterine artery resistance index (UARI) and thus allow for better blood flow and fetal outcomes during pregnancies stricken with placental ischemia. Doppler sonography will be performed on rats to measure UARI as an indicator of improved blood flow, which would allow for improved fetal growth in RUPP rat model of preeclampsia. This study could thereby establish proof of concept further supporting the addition of 17-OHPC to the current treatment for early preterm preeclampsia.
Materials and Methods
Sprague Dawley rats purchased from Harlan, Inc, (Indianapolis, IN) were used in the present study. Rats were housed in a temperaturecontrolled room (23°C) with a 12:12-hour light/dark cycle with free access to standard rat chow and water. This study complied with guidelines of the University of Mississippi Medical Center, and the animals were handled according to the guiding principles published in the National Institutes of Health Guide for the Care of Animals and the Institutional Animal Care and Use Committee.
Reduction of Uterine Perfusion Pressure
On day 14 of gestation, rat dams weighting ≈200 to 250 g were exposed to 2% isoflurane and randomly assigned to either RUPP or NP control groups. After a midline incision, pregnant rats in the RUPP group had the lower abdominal aorta isolated and a silver clip (0.203 mm ID) placed around the aorta above the iliac bifurcation. To prevent augmentation of blood flow to the uterus via the ovarian arteries, silver clips (0.100 mm ID) were also placed on the branches of both ovarian arteries that supply the uterus. 23 Also analgesics were used to provide comfort for the surgical rats include 0.25% sensor care administered topically or 5-mg/kg carprofen administered via subcutaneous injection, QD for 2 to 3 days after surgical procedure.
Administration of 17-OHPC
The 17-OHPC (Marty's Compounding Pharmacy, Jackson, MS) was diluted in normal saline and administered intraperitoneally as 0.5 cm 3 solution of 3.32 mg/kg 17-OHPC to pregnant rats on day 15 of gestation. This dose is equivalent to a typical human dose for the prevention of preterm labor previously and has been shown to be effective in RUPP rats to lower blood pressure when administered on day 18 of gestation.
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Measurement of Mean Arterial Blood Pressure
Pregnant rats were catheterized on day 18 of gestation under anesthesia using isoflurane (Webster, Sterling, MA) delivered by an anesthesia apparatus (Vaporizer for Forane Anesthetic; Ohio Medical Products, Madison, WI). On day 19 of gestation, mean arterial blood pressure was analyzed after placing the rats in individual restraining cages. Mean arterial blood pressure was recorded continuously for 1 hour after a 30-minute stabilization and calculated by mean arterial blood pressure=systolic blood pressure+2 (diastolic blood pressure)/3, as described previously.
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Determination of UARI
On day 18 of gestation, power Doppler velocimetry measurements were performed on anesthetized pregnant dams at an imaging station with a Vevo 770 U (Visual sonics) using a 30 Hz transducer and an insonating angle <30° as described previously. 2 The peak systolic flow velocity and end diastolic flow velocity were recorded using the uterine artery Doppler waveform, and the index was calculated using the following formula: UARI=(peak systolic flow velocity−end diastolic flow velocity)/peak systolic flow velocity.
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Determination of TNF-α
Plasma collected from all pregnant rats was measured for TNF-α levels using commercial ELISA kits from R&D Systems (Quantikine) according the manufacturer's instructions. The minimal detectable level for TNF-α was <5 pg/mL, with inter-and intra-assay variability of 10% and 5.1%, respectively.
Determination of sFlt-1
Plasma collected from all pregnant rats was measured for sFlt-1 levels using commercial ELISA kits from R&D Systems (Quantikine) according the manufacturer's instructions. The minimal detectable level for sFlt-1 was 15.2 pg/mL, with inter-and intra-assay variability of 8.4% and 7.2%.
Determination of Circulating Nitrate-Nitrite Bioavailability
Plasma nitrate-nitrite (NOx) levels were evaluated using commercial Nitrate-Nitrite Colorimetric Assay Kit from Cayman Chemical following instructions outlined by the manufacturer. The interassay coefficient of variation is 3.4%, whereas intra-assay coefficient of variation is 2.7%.
Statistical Analysis
All data are expressed as mean±SEM. Comparisons between groups were assessed by 2-way ANOVA with Bonferroni multiple comparisons test as post hoc analysis. A value of P <0.05 was considered statistically significant. Significant changes in pup weight and litter size were only seen with Student t test.
Results
Early Administration of 17-OHPC Improved Hypertension in RUPP Rats
Mean arterial blood pressure in NP (n=10) was 102±2 mm Hg, 105±2 mm Hg in NP+GD15 17-OHPC (n=7), and increased to 127±2 mm Hg in RUPP (n=14; P<0.05), which was improved to 111±1 mm Hg in RUPP+GD15 17-OHPC (n=17; P<0.05; Figure 1 ). Importantly, with 17-OHPC given in early gestation (GD15), blood pressure was blunted to a greater degree than seen in our previous study with 17-OHPC administrated in late gestation, day 18 of gestation (GD18), in RUPP rats.
Early Administration of 17-OHPC Decreased Plasma TNF-α Levels in RUPP Rats
To determine whether GD15 17-OHPC could reduce inflammation while decreasing blood pressure in response to placental ischemia, we analyzed circulating levels of TNF-α in plasma collected on day 19 of gestation. Plasma levels of TNF-α were 17±7 pg/mL in NP (n=6), 18±8 pg/mL in NP+GD15 17-OHPC (n=6), and 164±34 pg/mL in RUPP rats (n=7), which were blunted to 29±9 pg/mL (n=7,) in RUPP+GD15 17-OHPC (n=7; P<0.05; Figure 2A ).
Early Administration of 17-OHPC Increased Plasma Levels of Nitrate-Nitrite in RUPP Rats
To determine whether GD 15 17-OHPC increased NO bioavailability in RUPP rats, we analyzed circulating nitratenitrite (NOx). Previously, we have demonstrated that plasma NOx was decreased in RUPP compared with NP. 18 In this current study, plasma nitrate-nitrite (NOx) was 23.0±1.6 in NP (n=9), 26.6+3.5 in NP+GD15 17-OHPC (n=4), and 10.8±2.3 in RUPP rats (n=13), which improved to 25.5±5.2 µmol/L in RUPP+GD15 17-OHPC (n=5; P<0.05; Figure 2B ).
Early Administration of 17-OHPC Decreased sFlt-1 Levels in RUPP Rats
As we have published previously, sFlt-1 levels were increased in response to placental ischemia during pregnancy. sFlt-1 levels were 58.0±16.7 in NP (n=5), 115±25.5 in NP+17-OHPC, and 386±141 in RUPP rats, which were significantly reduced to 110.2±11 in RUPP+17-OHPC (n=7; P<0.05; Figure 2C ).
Early Administration of 17-OHPC Reduced UARI
As we have demonstrated previously, UARI was increased in response to placental ischemia during pregnancy, 18 similar to that seen in preeclampsia. In this study, UARI was 0.5±0.03 in NP (n=5), 0.5±0.02 in NP+GD15 17-OHPC, 0.8±0.03 in RUPP rats (n=4), and 0.6±0.04 in RUPP+GD15 17-OHPC (n=5; P<0.05; Figure 3 ).
Early Administration of 17-OHPC Improved Pup Weight and Litter Size in RUPP Rats
Consistent with preeclampsia, we have shown the decrease in pup weight in response to chronic placental ischemia in the RUPP rat. Pup weight was 2.3±0.04 in NP (n=10), 2.3±0.2 in NP+GD15 17-OHPC (n=7), and 1.9±0.05 g in RUPP rats (n=14; P<0.05). Interestingly, the pup weight was significantly improved to 2.1±0.07 g in RUPP rats treated with GD15 17-OHPC compared with untreated RUPP rats (n=15; P<0.05; Figure 4A ). In addition, litter size was 15.7±0.2 in NP (n=7) and 14.0±0.7 in NP+GD15 17-OHPC (n=7), which was significantly lower in RUPP rats (10. 1±1.4; n=10), and GD15 administration of 17-OHPC improved litter size to 13.2±0.60 in RUPP+GD15 17-OHPC (n=16) compared with RUPP rats (n=14; P<0.05; Figure 4B ).
Discussion
Clinical trials using either oral or vaginal progestogens for preeclampsia complication have been debated 25 ; however, there is no effective treatment approved for preeclampsia, except the early delivery of placenta. There are no data supporting the hypothesis that women receiving 17-OHPC for prevention of preterm labor have a lower incidence of preeclampsia. 25 17-OHPC is only given to women to prevent subsequent preterm birth; however, importantly, these women may not go on to develop preeclampsia but instead have an increased time to delivery. Importantly, previous studies have shown that circulating progesterone levels and urine metabolites of progesterone are decreased in intrauterine growth restriction, 26 and 17-OHPC may only benefit pregnant women with progesterone deficiency. Our ongoing clinical studies are investigating the potential use of 17-OHPC for the management of severe preeclampsia diagnosed before 34 weeks gestation.
Because the role of progestogens in this disease is still not fully understood, much more research should be performed to better understand the efficacy of progesterone supplementation to improve pregnancy outcomes in response to placental ischemia. Indeed, we have recently published that 17-OHPC administrated during late gestation to RUPP rats reduces inflammation, renal and placental ET-1, blood pressure, UARI, and increases vascular eNOS expression and NO bioavailability. 17, 18, 20 Importantly, our findings in the current study demonstrate that early administration of 17-OHPC on day 15 of gestation after placental ischemia has an even greater effect to improve many characteristics of preeclampsia in RUPP rats, further reducing hypertension compared with GD18 administration. Furthermore, we show that early administration of 17-OHPC also reduced signals of inflammation and UARI. Moreover, 17-OHPC increased NO bioavailability, pup weight, and litter size. Reduction in fetal weight is an important consequence of preeclampsia that was only improved with early administration and not late administration of 17-OHPC.
Interestingly, an important finding of this current study is that UARI significantly reduced with GD15 17-OHPC in RUPP rats. Even though the UARI during the first or second trimester of pregnancy may not be the best to predict complications during pregnancy, Doppler is useful as a primary indicator of placental ischemia and predictor of women who will go on to have troubled pregnancies, such as preeclampsia; these data demonstrate that 17-OHPC can improve this parameter within 3 days of injection and lead to improved fetal weight is extremely important. This preclinical data indicate that if 17-OHPC is administered midgestation after unusual Doppler assessment and then potentially blood flow, antiangiogenic factors and fetal weight could be improved to some degree in women that may go on to develop preeclampsia.
Numerous studies have shown decreased NO is associated with preeclampsia. [27] [28] [29] NO is an important vasodilator required to maintain the physiological alteration during normal pregnancy, such as an increased blood volume that is accommodated within cardiovascular system by systemic vasodilation. 30 In fact, animal and human studies have shown a deficiency of NO bioavailability during preeclampsia. 31 In agreement with these findings, in this study, we demonstrated that plasma levels of NO were reduced in RUPP rats compared with control NP rats and that 17-OHPC improved NO in RUPPs.
Furthermore, we have recently shown that hypertension caused by infusion of sFlt-1 is associated with endothelial dysfunction characterized by increased ET-1 and decreased NO. In this study, we show that 17-OHPC can reduce sFlt-1, which could allow for the increase in bioavailable NO. In turn, this would allow for the observed reduction in UARI-a possible indicator of endothelial dysfunction-and thus allow for increased blood and nutrient delivery to the fetus. Therefore, we think this could be the mechanisms for improved blood pressure and fetal weight observed in this study.
Proinflammatory cytokines, such as TNF-α and IL-6, have also been associated with preeclampsia.
12 Our laboratory has shown that TNF-α infusion into pregnant rats promotes sFlt-1 and hypertension during pregnancy. 16 Indeed, others have shown that in the vasculature, inflammation contributes to endothelial dysfunction-a hallmark feature of preeclampsia. 32 Our findings demonstrate that TNF-α was increased in RUPP rats compared with NP rats, and this increase was attenuated with early administration of 17-OHPC in RUPP rats. Previously, we have published that 17-OHPC given on late gestation (GD18) to RUPP rats decreased proinflammatory cytokines, such as TNF-α and IL-6. [18] [19] [20] Together, these results suggest that earlier intervention with a drug (17-OHPC) could improve TNF-α, sFlt-1, NO, and fetal growth while reducing the maternal pathophysiology associated with placental ischemia or preeclampsia during pregnancy.
In conclusion, although we have shown that GD18 administration of 17-OHPC attenuates pathophysiology of placental ischemia observed in RUPP rats, there were no fetal improvements in those studies. New to this study is that early administration (GD15) of 17-OHPC not only improves inflammation and sFlt-1, but it also reduced UARI and increased NO. This could be the mechanism for the further reduction in blood pressure compared with that seen with GD18 administration. Importantly, fetal characteristics, such as fetal weight and litter size, were significantly increased suggesting earlier intervention with 17-OHPC could have beneficial effects to not only improve maternal outcome but that of the baby, via improvements in the sFlt-1/NO pathway, and should be considered for the addition to the management of preeclampsia clinically.
Perspectives
Previous clinical trials using either oral or vaginal progestogens for preeclampsia complication were inconclusive concerning the role of progesterone in this important hypertensive disorder during pregnancy. It is well known that sFlt-1 plays a crucial role in the pathophysiology of preeclampsia. Our findings suggest that early administration of 17-OHPC improves important maternal and fetal outcomes during preeclampsia that may be stimulated by the increase in sFlt-1. Therefore, the discovery that 17-OHPC reduced sFlt-1 leads to a better understanding of mechanisms by which this drug can improve clinical characteristics of preeclampsia in response to placental ischemia and may offer greater positive benefits for both mother and child.
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What Is New?
• 17-Hydroxyprogesterone caproate (17-OHPC) administered on day 15 of gestation improved hypertension by suppressing TNF-α (tumor necrosis factor-α) and sFlt-1 (soluble vascular endothelial growth factor receptor 1) levels while improving pup weight, litter size, uterine artery resistance index, and NO bioavailability in response to placental ischemia during pregnancy.
What Is Relevant?
• 17-OHPC administered on day 15 of gestation suppresses sFlt-1, inflammation, and increases NO levels as mechanisms to improve uterine artery resistance index, intrauterine growth restriction while lowering maternal blood pressure in rat models of preeclampsia, thereby establishing proof of concept to support the addition of 17-OHPC to the current treatment for early preterm preeclampsia.
Summary
17-OHPC is not used in the management or treatment of preeclampsia but is routinely used for prevention of preterm labor. Our study illustrates that early administration of 17-OHPC on day 15 of gestation improves intrauterine growth restriction, NO bioavailability, and uterine artery resistance index, possibly via reducing sFlt-1 levels and inflammation while lowering blood pressure in response to placental ischemia. These data suggest that 17-OHPC could be administered early in gestation to patients, diagnosed between 22 and 30 weeks, and potential increase time to delivery and improve both fetal and maternal outcomes observed in response to placental ischemia.
Novelty and Significance
